CRP and acute respiratory distress syndrome: Sarilumab is a fully human antibody against the interleukin (IL)-6 receptor, which can rapidly lower C-reactive protein and mediate COVID-19 clearance.[76] Prolonged glucocorticoid treatment is associated with improved outcomes of acute respiratory distress syndrome.[77] Several reports have also shown that treatment with methylprednisolone could significantly reduce the risk of death among patients with acute respiratory distress syndrome.[78] This also accords with our observations, which suggested that methylprednisolone was associated with decreased ACM in severe COVID-19 patients.